- Home
- AES vs TECH Comparison
AES vs TECH Comparison
Compare AES & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- TECH
- Stock Information
- Founded
- AES 1981
- TECH 1976
- Country
- AES United States
- TECH United States
- Employees
- AES N/A
- TECH N/A
- Industry
- AES Electric Utilities: Central
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AES Utilities
- TECH Health Care
- Exchange
- AES Nasdaq
- TECH Nasdaq
- Market Cap
- AES 7.1B
- TECH 7.9B
- IPO Year
- AES 1991
- TECH 1989
- Fundamental
- Price
- AES $12.42
- TECH $48.34
- Analyst Decision
- AES Buy
- TECH Buy
- Analyst Count
- AES 8
- TECH 10
- Target Price
- AES $14.63
- TECH $73.44
- AVG Volume (30 Days)
- AES 15.1M
- TECH 2.4M
- Earning Date
- AES 05-01-2025
- TECH 05-07-2025
- Dividend Yield
- AES 5.67%
- TECH 0.66%
- EPS Growth
- AES 146.43
- TECH N/A
- EPS
- AES 1.83
- TECH 0.83
- Revenue
- AES $12,119,000,000.00
- TECH $1,208,770,000.00
- Revenue This Year
- AES $4.98
- TECH $8.19
- Revenue Next Year
- AES $2.40
- TECH $8.61
- P/E Ratio
- AES $6.80
- TECH $58.36
- Revenue Growth
- AES N/A
- TECH 4.72
- 52 Week Low
- AES $9.57
- TECH $46.44
- 52 Week High
- AES $22.21
- TECH $85.57
- Technical
- Relative Strength Index (RSI)
- AES 68.93
- TECH 39.46
- Support Level
- AES $10.19
- TECH $46.77
- Resistance Level
- AES $12.64
- TECH $54.40
- Average True Range (ATR)
- AES 0.41
- TECH 2.15
- MACD
- AES 0.33
- TECH 0.23
- Stochastic Oscillator
- AES 91.14
- TECH 8.82
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.